DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy.
Open accessAbstract
RATIONALE: Key biologic effects of the alpha-particle emitter Actinium-225 in comparison to the beta-particle emitter Lutetium-177 labeled somatostatin-analogue DOTATOC in vitro and in vivo were studied to evaluate the significance of γH2AX-foci formation. METHODS: To determine the relative biological effectiveness (RBE) between the two isotopes (as - biological consequence of different ionisation-densities along a particle-track), somatostatin expressing AR42J cells were incubated with Ac-225-DOTATOC and Lu-177-DOTATOC up to 48 h and viability was analyzed using the MTT assay. DNA double strand breaks (DSB) were quantified by immunofluorescence staining of γH2AX-foci. Cell cycle was analyzed by flow cytometry. In vivo uptake of both radiolabeled somatostatin-analogues into subcutaneously growing AR42J tumors and the number of cells displaying γH2AX-foci were measured. Therapeutic efficacy was assayed by monitoring tumor growth after treatment with activities estimated from in vitro cytotoxicity. RESULTS: Ac-225-DOTATOC resulted in ED50 values of 14 kBq/ml after 48 h, whereas Lu-177-DOTATOC displayed ED50 values of 10 MBq/ml. The number of DSB grew with increasing concentration of Ac-225-DOTATOC and similarly with Lu-177-DOTATOC when applying a factor of 700-fold higher activity compared to Ac-225. Already 24 h after incubation with 2.5-10 kBq/ml, Ac-225-DOTATOC cell-cycle studies showed up to a 60% increase in the percentage of tumor cells in G2/M phase. After 72 h an apoptotic subG1 peak was also detectable. Tumor uptake for both radio peptides at 48 h was identical (7.5%ID/g), though the overall number of cells with γH2AX-foci was higher in tumors treated with 48 kBq Ac-225-DOTATOC compared to tumors treated with 30 MBq Lu-177-DOTATOC (35% vs. 21%). Tumors with a volume of 0.34 ml reached delayed exponential tumor growth after 25 days (44 kBq Ac-225-DOTATOC) and after 21 days (34 MBq Lu-177-DOTATOC). CONCLUSION: γH2AX-foci formation, triggered by beta- and alpha-irradiation, is an early key parameter in predicting response to internal radiotherapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In vitro pancreatic tumor cells, 225Ac and 177Lu triggered gamma-H2AX-foci formation is an early key parameter in predicting response to internal radiotherapy.
“225Ac and 177Lu triggered-γH2AX-foci formation is an early key parameter in predicting response to internal radiotherapy.”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [156]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Single cell gel/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing
Tice, R. R., Agurell, E., Anderson, D. C., Burlinson, B., Hartmann, A., Kobayashi, H., Miyamae, Y., Rojas, E., Ryu, J., & Sasaki, Y. F. (2000) · Environmental and Molecular Mutagenesis · doi:10.1002/(sici)1098-2280(2000)35:3 · Cited by 4,864 · see citing works
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466 · see citing works
The comet assay: a method to measure DNA damage in individual cells
Olive, P. L., & Banáth, J. P. (2006) · Nature Protocols · doi:10.1038/nprot.2006.5 · Cited by 1,845 · see citing works
-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin
Kinner, A., Wu, W., Staudt, C., & Iliakis, G. E. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn550 · Cited by 1,249 · see citing works
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Reubi, J. C. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0007 · Cited by 1,128 · see citing works
Olive, P. L., Banáth, J. P., Durand, R. E., & Banáth, J. P. (1990) · Radiation Research · doi:10.2307/3577587 · Cited by 1,095 · see citing works
Olive, P. L., Banáth, J. P., & Durand, R. E. (2012) · Radiation Research · doi:10.1667/rrav04.1 · Cited by 1,031 · see citing works
Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552 · see citing works
Tumor therapy with targeted atomic nanogenerators.
McDevitt, M. R., Ma, D., Lai, L. T., Simon, J., Borchardt, P., Frank, R. K., Wu, K., Pellegrini, V., Curcio, M. J., Miederer, M., et al. (2001) · Science · doi:10.1126/science.1064126 · Cited by 501 · see citing works
Self-citationRadioimmunotherapy with alpha-emitting nuclides
McDevitt, M. R., Sgouros, G., Finn, R. D., Humm, J. L., Jurcic, J. G., Larson, S. M., & Scheinberg, D. A. (1998) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050306 · Cited by 403 · see citing works
Thompson, L. H. (2012) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2012.06.002 · Cited by 357 · see citing works
MIRD Pamphlet No. 24: Guidelines for Quantitative 131I SPECT in Dosimetry Applications
Dewaraja, Y. K., Ljungberg, M. H., Green, A. J., ZANZONICO, P. B., Frey, E. C., Bolch, W. E., Brill, A. B., Dunphy, M. P., Fisher, D. R., Howell, R. W., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.122390 · Cited by 335 · see citing works
Multiple roles of ATM in monitoring and maintaining DNA integrity
Derheimer, F. A., & Kastan, M. B. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.05.031 · Cited by 256 · see citing works
Lutetium-labelled peptides for therapy of neuroendocrine tumours
Kam, B. L. R., Teunissen, J. J. M., Krenning, E. P., de Herder, W. W., Khan, S., van Vliet, E. I., & Kwekkeboom, D. J. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2039-y · Cited by 247 · see citing works
Production of Ac-225 from Th-229 for Targeted α Therapy
Apostolidis, C., Molinet, R., Rasmussen, G., & Morgenstern, A. (2005) · Analytical Chemistry · doi:10.1021/ac0580114 · Cited by 215 · see citing works
Self-citationMiederer, M., Scheinberg, D. A., & McDevitt, M. R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.009 · Cited by 210 · see citing works
Self-citationHong, S., Hobbs, R. F., Vajravelu, R. K., Huso, D. L., Esaias, C. E., Apostolidis, C., Morgenstern, A., & Sgouros, G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1828 · Cited by 158 · see citing works
Self-citationMiederer, M., Henriksen, G., Alke, A., Mossbrugger, I., Quintanilla-Martinez, L., Senekowitsch-Schmidtke, R., & Essler, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4647 · Cited by 155 · see citing works
Self-citationBehr, T. M., Béhé, M. P., Stabin, M. G., Wehrmann, E., Apostolidis, C., Molinet, R., Strutz, F., Fayyazi, A., Wieland, E., Gratz, S., et al. (1999) · PubMed · Cited by 127 · see citing works
Clustered DNA damage induces pan-nuclear H2AX phosphorylation mediated by ATM and DNA–PK
Meyer, B., Voss, K., Tobias, F., Jakob, B., Durante, M., & Taucher-Scholz, G. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt304 · Cited by 112 · see citing works
Breaking Chemoresistance and Radioresistance with [213Bi]anti-CD45 Antibodies in Leukemia Cells
Friesen, C., Glatting, G., Koop, B., Schwarz, K., Morgenstern, A., Apostolidis, C., Debatin, K., & Reske, S. N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3569 · Cited by 98 · see citing works
Self-citationEssler, M., Gärtner, F. C., Neff, F., Blechert, B., Senekowitsch–Schmidtke, R., Bruchertseifer, F., Morgenstern, A., & Seidl, C. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2023-6 · Cited by 75 · see citing works
Self-citationNayak, T. K., Norenberg, J. P., Anderson, T. L., Prossnitz, E. R., Stabin, M. G., & Atcher, R. W. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2006.11.006 · Cited by 73 · see citing works
Wu, J., Clingen, P. H., Spanswick, V. J., Mellinas‐Gomez, M., Meyer, T., Puzanov, I. J., Jodrell, D. I., Hochhauser, D., & Hartley, J. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2529 · Cited by 65 · see citing works
Targeted alpha therapy with 213Bi.
Morgenstern, A., Bruchertseifer, F., & Apostolidis, C. (2011) · Current Radiopharmaceuticalse · doi:10.2174/1874471011104040295 · Cited by 58 · cited 1× · see citing works
“, Actinium-225 ((225)Ac) and Bismuth-213 ((213)Bi) were described in vitro and in vivo [4,5].”
BackgroundSelf-citationGamma-H2AX foci in cells exposed to a mixed beam of X-rays and alpha particles
Staaf, E., Brehwens, K., Haghdoost, S., Czub, J., & Wójcik, A. (2012) · Genome Integrity · doi:10.1186/2041-9414-3-8 · Cited by 52 · see citing works
Repetto‐Llamazares, A. H. V., Larsen, R. H., Mollatt, C., Laßmann, M., & Dahle, J. (2013) · Current Radiopharmaceuticals · doi:10.2174/1874471011306010004 · Cited by 48 · see citing works
Cancer Therapy with Alpha-Emitters Labeled Peptides
Dadachova, E. (2010) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2010.01.002 · Cited by 40 · see citing works
Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells
Haro, K. J., Scott, A., & Scheinberg, D. A. (2012) · Blood · doi:10.1182/blood-2012-01-404509 · Cited by 39 · see citing works
Roscher, M., Hormann, I., Leib, O., Marx, S., Moreno, J., Miltner, E., & Friesen, C. (2013) · Oncotarget · doi:10.18632/oncotarget.817 · Cited by 34 · see citing works
Proteomic analysis of apoptotic and oncotic pancreatic acinar AR42J cells treated with caerulein
Chu, J., Hongliang, J., Lu, M., Li, Z., Qiao, X., Sun, B., Zhang, W., & Xue, D. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1603-0 · Cited by 18 · see citing works
Effects of Arsenic Trioxide on the Cerulein-Induced AR42J Cells and Its Gene Regulation
Xue, D., Zhang, W., Liang, T., Zhao, S., Sun, B., & Sun, D. (2009) · Pancreas · doi:10.1097/mpa.0b013e3181b65dec · Cited by 7 · see citing works
White, J. S., Yue, N. J., Hu, J., & Bakkenist, C. J. (2011) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2011.01.005 · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Baum, R. P., Schuchardt, C., Singh, A., Chantadisai, M., Robiller, F., Zhang, J., Müeller, D., Eismant, A., Almaguel, F. A., Zboralski, D., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.259192 · Cited by 379 · see citing works
Khreish, F., Ebert, N., Ries, M., Maus, S., Rosar, F., Bohnenberger, H., Stemler, T., Saar, M., Bartholomä, M. D., & Ezziddin, S. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04612-0 · Cited by 219 · see citing works
Self-citationDevelopment of <sup>225</sup>Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
Robertson, A. K. H., Ramogida, C. F., Schaffer, P., & Radchenko, V. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471011666180416161908 · Cited by 202 · see citing works
Marcu, L. G., Bezak, E., & Allen, B. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.01.001 · Cited by 147 · see citing works
Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches
Thiele, N. A., & Wilson, J. J. (2018) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2018.2494 · Cited by 141 · see citing works
Current, K., Meyer, C. A. L., Magyar, C. E., Mona, C. E., Almajano, J., Slavik, R., Stuparu, A. D., Cheng, C., Dawson, D. W., Radu, C. G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1485 · Cited by 124 · see citing works
Evaluation of an Anti-HER2 Nanobody Labeled with 225Ac for Targeted α-Particle Therapy of Cancer
Pruszyński, M., D’Huyvetter, M., Bruchertseifer, F., Morgenstern, A., & Lahoutte, T. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00985 · Cited by 116 · see citing works
Self-citationHagemann, U. B., Ellingsen, C., Schuhmacher, J., Kristian, A., Mobergslien, A., Cruciani, V., Wickstroem, K., Schatz, C. A., Kneip, C., Golfier, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3476 · Cited by 115 · see citing works
Theranostic radiopharmaceuticals: established agents in current use
Ballinger, J. R. (2018) · British Journal of Radiology · doi:10.1259/bjr.20170969 · Cited by 114 · see citing works
α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies—Part 2
Poty, S., Francesconi, L. C., McDevitt, M. R., Morris, M. J., & Lewis, J. S. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.204651 · Cited by 113 · see citing works
Sharma, R., Wang, W. M., Yusuf, S., Evans, J. S., Ramaswami, R., Wernig, F., Frilling, A., Mauri, F. A., AL-NAHHAS, A. M., Aboagye, E. O., et al. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.09.003 · Cited by 108 · see citing works
Unboxing the molecular modalities of mutagens in cancer
Kumari, S., Sharma, S., Advani, D., Khosla, A., Kumar, P., & Ambasta, R. K. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-16726-w · Cited by 105 · see citing works
Navalkissoor, S., & Grossman, A. B. (2018) · Neuroendocrinology · doi:10.1159/000494760 · Cited by 99 · see citing works
Ohshima, Y., Sudo, H., Watanabe, S., Nagatsu, K., Tsuji, A. B., Sakashita, T., Ito, Y. M., Yoshinaga, K., Higashi, T., & Ishioka, N. S. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3919-6 · Cited by 94 · see citing works
The in vivo fate of 225Ac daughter nuclides using polymersomes as a model carrier
de Kruijff, R. M., Raavé, R., Kip, A., Molkenboer‐Kuenen, J. D. M., Morgenstern, A., Bruchertseifer, F., Heskamp, S., & Denkova, A. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-48298-8 · Cited by 93 · see citing works
Self-citationRecent advances and impending challenges for the radiopharmaceutical sciences in oncology
Lapi, S. E., Scott, P. J. H., Scott, A. M., Windhorst, A. D., Zeglis, B. M., Abdel–Wahab, M., Baum, R. P., Buatti, J. M., Giammarile, F., Kiess, A. P., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00030-5 · Cited by 90 · see citing works
Hooijman, E. L., Radchenko, V., Ling, S. W., Konijnenberg, M., Brabander, T., Koolen, S. L. W., & de Blois, E. (2024) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-024-00239-1 · Cited by 88 · see citing works
Harnessing α -Emitting Radionuclides for Therapy: Radiolabeling Method Review
Yang, H., Wilson, J. J., Orvig, C., Li, Y., Wilbur, D. S., Ramogida, C. F., Radchenko, V., & Schaffer, P. C. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262687 · Cited by 87 · see citing works
Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window
Kelly, J. M., Amor‐Coarasa, A., Ponnala, S., Nikolopoulou, A., Williams, C. M., DiMagno, S. G., & Babich, J. W. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.221150 · Cited by 85 · see citing works
232 Th-Spallation-Produced 225 Ac with Reduced 227 Ac Content
Robertson, A. K. H., McNeil, B. L., Yang, H., Gendron, D., Perron, R., Radchenko, V., Zeisler, S., Causey, P. W., & Schaffer, P. C. (2020) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.0c01081 · Cited by 85 · see citing works
Implementing f-Block Metal Ions in Medicine: Tuning the Size Selectivity of Expanded Macrocycles
Thiele, N. A., Woods, J. J., & Wilson, J. J. (2019) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.9b01277 · Cited by 82 · see citing works
The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research
Ruigrok, E. A. M., van Weerden, W. M., Nonnekens, J., & de Jong, M. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11110560 · Cited by 75 · see citing works
Alpha-Emitting Radionuclides: Current Status and Future Perspectives
Miederer, M., Benešová, M., Mamat, C., Kästner, D., Pretze, M., Michler, E., Brogsitter, C., Kotzerke, J., Kopka, K., Scheinberg, D. A., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17010076 · Cited by 71 · see citing works
Self-citationAn efficient chelator for complexation of thorium-227
Ramdahl, T., Bonge‐Hansen, H. T., Ryan, O. B., Larsen, Å., Herstad, G., Sandberg, M., Bjerke, R. M., Grant, D., Brevik, E. M., & Cuthbertson, A. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.07.034 · Cited by 71 · see citing works
Salvanou, E.-A., Stellas, D., Tsoukalas, C., Mavroidi, B., Paravatou‐Petsotas, M., Kalogeropoulos, N., Xanthopoulos, S., Denat, F., Laurent, G., Bazzi, R., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020188 · Cited by 71 · see citing works
Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68 · see citing works
A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma
Bolcaen, J., Kleynhans, J., Nair, S., Verhoeven, J., Goethals, I., Sathekge, M. M., Vandevoorde, C., & Ebenhan, T. (2021) · Theranostics · doi:10.7150/thno.56639 · Cited by 68 · see citing works
Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs
Miller, C., Rousseau, J., Ramogida, C. F., Celler, A. M., Rahmim, A., & Uribe, C. (2021) · Theranostics · doi:10.7150/thno.62851 · Cited by 67 · see citing works
Purohit, N. K., Shah, R. G., Adant, S., Hoepfner, M., Shah, G. M., & Beauregard, J. (2018) · Oncotarget · doi:10.18632/oncotarget.25266 · Cited by 64 · see citing works
Ramogida, C. F., Robertson, A. K. H., Jermilova, U., Zhang, C., Yang, H., Kunz, P., Lassen, J., Bratanovic, I., Brown, V., Southcott, L., et al. (2019) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-019-0072-5 · Cited by 64 · see citing works
Therapeutic Efficacy of 213Bi-labeled sdAbs in a Preclinical Model of Ovarian Cancer
Dekempeneer, Y., Caveliers, V., Ooms, M., Maertens, D., Gysemans, M., Lahoutte, T., Xavier, C., Lecocq, Q., Maes, K., Covens, P., et al. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00580 · Cited by 61 · see citing works
Self-citationDNA Damage by Radiopharmaceuticals and Mechanisms of Cellular Repair
Monfared, Y. K., Heidari, P., Klempner, S. J., Mahmood, U., Parikh, A. R., Hong, T. S., Strickland, M. R., & Esfahani, S. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122761 · Cited by 58 · see citing works
In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy
Chan, H. S., de Blois, E., Morgenstern, A., Bruchertseifer, F., de Jong, M., Breeman, W. A. P., & Konijnenberg, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181473 · Cited by 53 · see citing works
Self-citationDNA repair by MGMT, but not AAG, causes a threshold in alkylation-induced colorectal carcinogenesis
Fahrer, J., Frisch, J., Nagel, G., Kraus, A., Dörsam, B., Thomas, A. D., Reißig, S., Waisman, A., & Kaina, B. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv114 · Cited by 52 · see citing works
Self-citationFakiri, M. E., Geis, N. M., Ayada, N., Eder, M., & Eder, A.-C. (2021) · Cancers · doi:10.3390/cancers13163967 · Cited by 51 · see citing works
Somatostatin Receptor Based Imaging and Radionuclide Therapy
Xu, C., & Zhang, H. (2015) · BioMed Research International · doi:10.1155/2015/917968 · Cited by 49 · see citing works
Deblonde, G. J. ‐., Lohrey, T. D., Booth, C. H., Carter, K. P., Parker, B. F., Larsen, Å., Smeets, R., Ryan, O. B., Cuthbertson, A., & Abergel, R. J. (2018) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.8b02430 · Cited by 49 · see citing works
In vitro evaluation of 225Ac‐DOTA‐substance P for targeted alpha therapy of glioblastoma multiforme
Majkowska‐Pilip, A., Rius, M., Bruchertseifer, F., Apostolidis, C., Weis, M., Bonelli, M., Laurenza, M., Królicki, L., & Morgenstern, A. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13199 · Cited by 48 · see citing works
Self-citationRadionuclide Therapy in Prostate Cancer: From Standalone to Combination PSMA Theranostics
Sandhu, S. K., Guo, C. W., & Hofman, M. S. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.243295 · Cited by 47 · see citing works
Capturing an elusive but critical element: Natural protein enables actinium chemistry
Deblonde, G. J. ‐., Mattocks, J. A., Dong, Z., Wooddy, P. T., Cotruvo, J. A., & Zavarin, M. (2021) · Science Advances · doi:10.1126/sciadv.abk0273 · Cited by 44 · see citing works
Evaluation of 134 Ce/ 134 La as a PET Imaging Theranostic Pair for 225 Ac α-Radiotherapeutics
Bobba, K. N., Bidkar, A. P., Meher, N., Fong, C. O. Y., Wadhwa, A., Dhrona, S., Sorlin, A. M., Bidlingmaier, S. M., Shuere, B., He, J., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.265355 · Cited by 42 · see citing works
Rubira, L., Deshayes, E., Santoro, L., Kotzki, P. O., & Fersing, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041051 · Cited by 40 · see citing works
Lee, D., Li, M., Liu, D., Baumhover, N. J., Sagastume, E. A., Marks, B. M., Rastogi, P., Pigge, F. C., Menda, Y., Johnson, F. L., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06494-9 · Cited by 37 · see citing works
Gawęda, W., Osial, M. E., Żuk, M., Pękała, M., Bilewicz, A., & Krysiński, P. (2020) · Nanomaterials · doi:10.3390/nano10020288 · Cited by 35 · see citing works
Lakes, A. L., An, D. D., Gauny, S. S., Ansoborlo, C., Liang, B. H., Rees, J. A., McKnight, K. D., Karsunky, H., & Abergel, R. J. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00703 · Cited by 34 · see citing works
Hassan, M., Bokhari, T. H., Lodhi, N. A., Khosa, M. K., & Usman, M. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14311 · Cited by 33 · see citing works
Peptide Receptor Radionuclide Therapy in Thyroid Cancer
Gubbi, S., Koch, C. A., & Kłubo-Gwieździńska, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.896287 · Cited by 33 · see citing works
Sugyo, A., Tsuji, A. B., Sudo, H., Okada, M., Koizumi, M., Satoh, H., Kurosawa, G., Kurosawa, Y., & Saga, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123761 · Cited by 33 · see citing works
Lee, D., Li, M., Bednarz, B. P., & Schultz, M. K. (2018) · Radiation Research · doi:10.1667/rr15081.1 · Cited by 32 · see citing works
Morgan, K. A., Wichmann, C. W., Osellame, L. D., Cao, Z., Guo, N. Y., Scott, A. M., & Donnelly, P. S. (2024) · Chemical Science · doi:10.1039/d3sc06365h · Cited by 31 · see citing works
Falzone, N., Ackerman, N. L., Rosales, L. D. L. F., Bernal, M. A., Liu, X., Peeters, S. G. J. A., Soto, M. S., Corroyer‐Dulmont, A., Bernaudin, M., Grimoin, E., et al. (2017) · Theranostics · doi:10.7150/thno.22217 · Cited by 31 · see citing works
Reissig, F., Hübner, R., Steinbach, J., Pietzsch, H., & Mamat, C. (2019) · Inorganic Chemistry Frontiers · doi:10.1039/c9qi00208a · Cited by 31 · see citing works
Malo, M. E., Allen, K. J. H., Jiao, R., Frank, C., Rickles, D. J., & Dadachova, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228721 · Cited by 29 · see citing works
Arbuznikova, D., Eder, M., Grosu, A., Meyer, P. T., Gratzke, C., Zamboglou, C., & Eder, A.-C. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01458-6 · Cited by 29 · see citing works
Wickstroem, K., Hagemann, U. B., Kristian, A., Ellingsen, C., Sommer, A., Ellinger-Ziegelbauer, H. C., Wirnitzer, U., Hagelin, E.-M., Larsen, A., Smeets, R., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.06.2508 · Cited by 27 · see citing works
Arbuznikova, D., Klotsotyra, A., Uhlmann, L., Domogalla, L.-C., Steinacker, N., Mix, M. D., Niedermann, G., Spohn, S. K. B., Freitag, M. T., Grosu, A., et al. (2024) · Theranostics · doi:10.7150/thno.93249 · Cited by 26 · see citing works
Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review
Gape, P. M. D., Schultz, M. K., Stasiuk, G. J., & Terry, S. Y. A. (2024) · Pharmaceuticals · doi:10.3390/ph17030334 · Cited by 26 · see citing works
Roos, W. P., Quirós, S., Krumm, A., Merz, S., Switzeny, O. J., Christmann, M., Loquai, C., & Kaina, B. (2014) · Oncotarget · doi:10.18632/oncotarget.2610 · Cited by 25 · see citing works
Self-citationHan, G., Hwang, E., Lin, F., Clift, R., Kim, D., Guest, M., Bischoff, E. D., Moran, S. E., & Li, G. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0029 · Cited by 24 · see citing works
Deshayes, E., Ladjohounlou, R., Fur, P. L., Pichard, A., Lozza, C., Boudousq, V., Sevestre, S., Jarlier, M., Kashani, R., Joanna, K., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.208611 · Cited by 24 · see citing works
Self-citationLiberal, F. D. C. G., Moreira, H., Redmond, K. M., O’Sullivan, J. M., Alshehri, A. H. D., Wright, T., Dunne, V. L., Campfield, C., Biggart, S., McMahon, S. J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877302 · Cited by 23 · see citing works
Fakiri, M. E., Ayada, N., Müller, M., Hvass, L., Gamzov, T. H., Clausen, A. S., Geis, N. M., Steinacker, N., Hansson, E., Lindegren, S., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.267043 · Cited by 23 · see citing works
DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay
Schmeiser, H. H., Muehlbauer, K., Mier, W., Baranski, A.-C., Neels, O. C., Dimitrakopoulou‐Strauss, A., Schmezer, P., Kratochwil, C., Bruchertseifer, F., Morgenstern, A., et al. (2019) · Mutagenesis · doi:10.1093/mutage/gez007 · Cited by 23 · see citing works
Self-citationSpoormans, K., Crabbé, M., Struelens, L., Saint‐Hubert, M. D., & Koole, M. J. B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102007 · Cited by 22 · see citing works
Poty, S., Mandleywala, K., O’Neill, E. S., Knight, J. C., Cornelissen, B. T., & Lewis, J. S. (2020) · Theranostics · doi:10.7150/thno.44772 · Cited by 22 · see citing works
Preparation of an Actinium-228 Generator
Aldrich, K. E., Lam, M. N., Eiroa-Lledo, C., Kozimor, S. A., Lilley, L. M., Mocko, V., & Stein, B. W. (2020) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.9b03563 · Cited by 21 · see citing works
Cytryniak, A., Żelechowska-Matysiak, K., Nazaruk, E., Bilewicz, R., Walczak, R., Majka, E., Mames, A., Bruchertseifer, F., Morgenstern, A., Bilewicz, A., et al. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00182 · Cited by 20 · see citing works
Self-citationSPECT imaging of 226 Ac as a theranostic isotope for 225 Ac radiopharmaceutical development
Koniar, H., Rodríguez‐Rodríguez, C., Radchenko, V., Yang, H., Kunz, P., Rahmim, A., Uribe, C., & Schaffer, P. C. (2022) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ac8b5f · Cited by 20 · see citing works
D’Andrea, M. A., VanderWalde, N. A., Ballo, M. T., Patra, P., Cohen, G. N., Damato, A. L., & Barker, C. A. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.12824 · Cited by 20 · see citing works
Evaluation of 134Ce as a PET imaging surrogate for antibody drug conjugates incorporating 225Ac
Bailey, T. A., Wacker, J. N., An, D. D., Carter, K. P., Davis, R. C., Mocko, V., Larrabee, J., Shield, K. M., Lam, M. N., Booth, C. H., et al. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.04.007 · Cited by 20 · see citing works
Crumbaker, M., Emmett, L., Horvath, L. G., & Joshua, A. M. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00237 · Cited by 20 · see citing works
Tamborino, G., Nonnekens, J., Saint‐Hubert, M. D., Struelens, L., Feijtel, D., de Jong, M., & Konijnenberg, M. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262122 · Cited by 19 · see citing works
Design of 225Ac-PSMA for targeted alpha therapy in prostate cancer
Kairemo, K., Kgatle, M. M., Bruchertseifer, F., Morgernstern, A., & Sathekge, M. M. (2024) · Annals of Translational Medicine · doi:10.21037/atm-23-1842 · Cited by 18 · see citing works
Self-citationOptimal usage of radium-223 in metastatic castration-resistant prostate cancer
Cha, T., Wu, T. T.-L., Vogelzang, N. J., Huang, C., Huang, S., Lin, C.-C., Ou, Y., Pang, S., Shen, D. H.-Y., Wu, W., et al. (2017) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2017.04.005 · Cited by 17 · see citing works
Prostate specific membrane antigen binding radiopharmaceuticals: Current data and new concepts
Sartor, O. A., & Baghian, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1060922 · Cited by 16 · see citing works
Mapanao, A. K., Busslinger, S. D., Mehta, A., Kegler, K., Favaretto, C., Grundler, P. V., Talip, Z., Köster, U., Johnston, K., Schibli, R., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-07035-8 · Cited by 16 · see citing works
Role of bromodomain and extraterminal (BET) proteins in prostate cancer
Mandl, A., Markowski, M. C., Carducci, M. A., & Antonarakis, E. S. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2186851 · Cited by 16 · see citing works
Müller, M., Pedersen, N. B., Shalgunov, V., Jensen, A. I., Battisti, U. M., & Herth, M. M. (2025) · Medicinal Research Reviews · doi:10.1002/med.70008 · Cited by 15 · see citing works
Mechanisms of Resistance in Gastroenteropancreatic Neuroendocrine Tumors
Shi, C., & Morse, M. A. (2022) · Cancers · doi:10.3390/cancers14246114 · Cited by 15 · see citing works
Genetic Code Expansion for Site-Specific Labeling of Antibodies with Radioisotopes
Koehler, C., Sauter, P. F., Klasen, B., Waldmann, C. M., Pektor, S., Bausbacher, N., Lemke, E. A., & Miederer, M. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.2c00634 · Cited by 15 · see citing works
Self-citationRadiation Safety Considerations and Clinical Advantages of α-Emitting Therapy Radionuclides
Serencsits, B., Chu, B. P., Pandit-Taskar, N. D., McDevitt, M. R., & Dauer, L. T. (2021) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.121.262294 · Cited by 14 · see citing works
Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo
Bernabeu, T. B., Pektor, S., Bermudez, J. M., Meneses, N., Heller, M., Galván, J. A., Boligan, K. F., Schürch, S., von Gunten, S., Türler, A., et al. (2018) · Pharmaceuticals · doi:10.3390/ph11040132 · Cited by 14 · see citing works
Self-citation225Ac-iPSMA-RGD for Alpha-Therapy Dual Targeting of Stromal/Tumor Cell PSMA and Integrins
Ocampo‐García, B., Cruz-Nova, P., Jiménez‐Mancilla, N., Luna‐Gutiérrez, M., Oros‐Pantoja, R., Lara-Almazán, N., Pérez-Velasco, D. L., Santos‐Cuevas, C., & Ferro‐Flores, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316553 · Cited by 13 · see citing works
Matazova, E. V., Egorova, B. V., Zubenko, A. D., Вячеславовна, П. А., Mitrofanov, A. A., Fedorova, O. A., Ermolaev, S. V., Vasiliev, A. N., & Kalmykov, S. N. (2023) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.3c00314 · Cited by 13 · see citing works
Potent candidates for Targeted Alpha Therapy (TAT)
Filosofov, D. V., Baimukhanova, A., Khushvaktov, J., Kurakina, E. S., & Radchenko, V. (2025) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2025.109027 · Cited by 12 · see citing works
Tamborino, G., Perrot, Y., Saint‐Hubert, M. D., Struelens, L., Nonnekens, J., de Jong, M., Konijnenberg, M., & Villagrasa, C. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262610 · Cited by 11 · see citing works
Briest, F., Koziolek, E. J., Albrecht, J., Schmidt, F., Bernsen, M. R., Haeck, J. C., Kühl, A. A., Sedding, D., Hartung, T., Exner, S., et al. (2020) · Neoplasia · doi:10.1016/j.neo.2020.11.004 · Cited by 11 · see citing works
Plas, P., Limana, L., Carré, D., Thiongane, A., Raguin, O., Mansi, R., Meyer-Losic, F., & Lezmi, S. (2022) · Pharmaceuticals · doi:10.3390/ph15091085 · Cited by 10 · see citing works
Qin, Y., Imobersteg, S., Stephan, F., Blanc, A., Chiorazzo, T., Berger, P., Schibli, R., Béhé, M. P., & Grzmil, M. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264597 · Cited by 9 · see citing works
Development of Drugs and Technology for Radiation Theragnosis
Jeong, H.-J., Lee, B. C., Ahn, B., & Kang, K. W. (2016) · Nuclear Engineering and Technology · doi:10.1016/j.net.2016.04.003 · Cited by 9 · see citing works
Lim, A., Andriotty, M., Yusufaly, T., Agasthya, G. A., Lee, B., & Wang, C. C. (2023) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2023.1284558 · Cited by 8 · see citing works
Grzmil, M., Imobersteg, S., Blanc, A., Frank, S., Schibli, R., & Béhé, M. P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122156 · Cited by 8 · see citing works
Alpha emitting nuclides in nuclear medicine theranostics
Miederer, M. (2021) · Nuklearmedizin - NuclearMedicine · doi:10.1055/a-1650-9995 · Cited by 8 · see citing works
Self-citationNjotu, F. N., Ketchemen, J. P., Babeker, H., Henning, N. W., Tikum, A. F., Nwangele, E., Monzer, A., Hassani, N., Gray, B. D., Pak, K. Y., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-07011-2 · Cited by 7 · see citing works
Berg‐Larsen, A., Mobergslien, A., Moen, I. N., Petros, G., Kristian, A., Sponheim, K., Cruciani, V., Wickstroem, K., Bjerke, R. M., Karlsson, J., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1033303 · Cited by 7 · see citing works
Radiolabeling of Theranostic Nanosystems
Das, S., Imlimthan, S., Airaksinen, A. J., & Sarparanta, M. P. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-58174-9_3 · Cited by 7 · see citing works
Advances in PSMA-Targeted Radionuclide Therapeutics
Ruder, S. F., Ricaurte‐Fajardo, A., Sun, M., Castellanos, S. H., Osborne, J. R., & Tagawa, S. T. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01296-7 · Cited by 6 · see citing works
Palangka, C. R. A. P., Mahendra, I., Ritawidya, R., Kondo, N., & Nakajima, T. (2025) · Pharmaceuticals · doi:10.3390/ph18091316 · Cited by 6 · see citing works
Detecting radio- and chemoresistant cells in 3D cancer co-cultures using chromatin biomarkers
Pekeč, T., Venkatachalapathy, S., Shim, A. R., Paysan, D., Grzmil, M., Schibli, R., Béhé, M. P., & Shivashankar, G. V. (2023) · Scientific Reports · doi:10.1038/s41598-023-47287-2 · Cited by 6 · see citing works
The Power of Precision: Unravelling the Radiobiology of Targeted Radionuclide Therapy
Khanna, R., Gape, P. M. D., Grayson, K., Patel, M., & Terry, S. Y. A. (2025) · Clinical Oncology · doi:10.1016/j.clon.2025.103923 · Cited by 5 · see citing works
- Authors
- Graf, F., Fahrer, J., Maus, S., Morgenstern, A., Bruchertseifer, F., Venkatachalam, S., Fottner, C., Weber, M. M., Huelsenbeck, J., Schreckenberger, M., Kaina, B., & Miederer, M.
- Affiliations
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- European Commission (BE)
- Corresponding author
- Miederer, Matthias
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-02-07
- Volume
- 9
- Issue
- 2
- Pages
- e88239
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3917860
- OpenAlex
- W1984398166
- Cited by
- 143
- References
- 33
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 18 · 2023: 19 · 2022: 12 · 2021: 17 · 2020: 12 · 2019: 16 · 2018: 15 · 2017: 5 · 2016: 5 · 2015: 3 · 2014: 1
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Gutenberg Open Science (submittedVersion, cc-by-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Joint Research Centre (European Commission) (submittedVersion)
- Gutenberg Open Science (cc-by)
- Funders
- Bundesministerium für Bildung und Forschung
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Radiation Therapy and Dosimetry
- Keywords
- actinium-225, lutetium-177, somatostatin receptors, targeted radiotherapy, alpha-emitting radionuclides, DNA double-strand breaks, γH2AX foci, relative biological effectiveness, DOTATOC, AR42J cells, tumor cell cycle, apoptosis, tumor uptake, treatment efficacy, somatostatin analogues
- MeSH terms
- Actinium, Alpha Particles, Animals, Cell Cycle, Lutetium, Radioisotopes, Cell Death, Receptors, Somatostatin, Neuroendocrine Tumors, Cell Line, Tumor, Rats, DNA Breaks, Double-Stranded
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
